Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
G2Gbio Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are divided between 2 distinct art units and distinct examiners, meaning each active application is being reviewed by a different person in a different technical group. This lack of overlap indicates that the company's current prosecution is split across separate specialized fields within biotechnology.
SUSAN T TRAN is the busiest examiner for this applicant. This examiner is currently responsible for 1 pending office action. With pending office actions in total, the company must coordinate its responses across the 2 distinct art units, which may have different internal guidelines or timelines for pharmaceutical applications.
The involvement of distinct examiners for pending office actions highlights a distributed workload. SUSAN T TRAN and the other examiner each handle a single matter, requiring the applicant to maintain separate communication channels for each filing. This structure across the distinct art units ensures that the company's innovations are being evaluated by specialists in different technical niches of the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
| EVANS, JASMINE AFIYA | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18654262 | PHARMACEUTICAL KIT FOR PARENTERAL CO-ADMINISTRATION | EVANS, JASMINE AFIYA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18764541 | SUSTAINED-RELEASE INJECTION PREPARATION CONTAINING DONEPEZIL AND PREPARATION METHOD THEREFOR | TRAN, SUSAN T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18764541 | SUSTAINED-RELEASE INJECTION PREPARATION CONTAINING DONEPEZIL AND PREPARATION METHOD THEREFOR | TRAN, SUSAN T | 1615 | §103 | Non-Final OA | — | Pending | Jul 05, 2024 |
| 18654262 | PHARMACEUTICAL KIT FOR PARENTERAL CO-ADMINISTRATION | EVANS, JASMINE AFIYA | 1616 | §102§103§112 | Non-Final OA | — | Pending | May 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial